Merck KGaA's Exploring Of DNA-PK In Cancer ‘Unchanged’ By Vertex Gene-Editing Deal
Merck KGaA says a gene-editing deal last month with Vertex Pharma involving DNA-dependent protein kinase inhibitors will not alter its plans to investigate DNA-PK compounds in cancer, to try to enhance the efficacy of many commonly used DNA-damaging agents.
You may also be interested in...
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.
Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.